Acelyrin (NASDAQ:SLRN - Get Free Report)'s stock had its "neutral" rating restated by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 134.60% from the company's previous close.
Several other equities research analysts have also weighed in on SLRN. Piper Sandler cut their target price on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. Morgan Stanley reduced their target price on Acelyrin from $13.00 to $6.00 and set an "equal weight" rating on the stock in a report on Monday, August 19th. Finally, Wells Fargo & Company boosted their target price on Acelyrin from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday, October 16th.
View Our Latest Research Report on SLRN
Acelyrin Price Performance
Shares of Acelyrin stock traded down $0.65 during trading on Wednesday, hitting $3.41. 3,269,300 shares of the company were exchanged, compared to its average volume of 1,000,766. The firm has a market capitalization of $342.13 million, a P/E ratio of -1.35 and a beta of 1.63. The firm's fifty day moving average price is $5.29 and its 200 day moving average price is $5.02. Acelyrin has a 1-year low of $3.18 and a 1-year high of $8.89.
Institutional Investors Weigh In On Acelyrin
Institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC bought a new stake in shares of Acelyrin in the second quarter valued at about $590,000. Almitas Capital LLC acquired a new stake in Acelyrin in the 2nd quarter valued at approximately $1,659,000. Los Angeles Capital Management LLC acquired a new position in Acelyrin during the 2nd quarter worth approximately $693,000. Acuta Capital Partners LLC bought a new position in shares of Acelyrin during the 3rd quarter worth approximately $1,795,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Acelyrin by 218.0% in the second quarter. Renaissance Technologies LLC now owns 397,618 shares of the company's stock valued at $1,753,000 after purchasing an additional 272,600 shares during the last quarter. 87.31% of the stock is owned by institutional investors.
About Acelyrin
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
See Also
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
